House Committee Expands Investigation into Tainted Heparin - - BioPharm International

ADVERTISEMENT

House Committee Expands Investigation into Tainted Heparin


BioPharm Bulletin

Members of the House Energy and Commerce Committee are expanding their investigation into the 2008 entry of contaminated heparin from China into the United States (US) market.

Heparin contaminated with overly sulfated chondroitin sulfate was linked to adverse reactions and the deaths of dozens of patients. FDA determined that the contaminant was deliberately introduced, but neither the source of the contaminant nor those responsible has ever been identified.

Members of the committee have sent letters to 10 companies requesting further information on the Chinese heparin industry and the Chinese heparin supply chain. Those companies include Amphastar Pharmaceuticals, Momenta Pharmaceuticals, Siegfried USA, Sagent Pharmaceutical, APP Pharmaceuticals, Sanofi, Drug Source, Global Pharma Sourcing, Pacific Rainbow, and Sandoz.

In a press release, committee leaders wrote: “We believe there is substantial public interest in solving this case. More than 80 percent of the [US] unfractionated heparin supply is sourced from China and more than 16 percent of [US] pharmaceutical ingredients are imported from China. There is reason to believe all or some of the individuals responsible for the adulteration are still actively engaged in the Chinese pharmaceutical supply chain and pose a continuing threat to pharmaceutical products imported to the [US]. How the heparin came to be contaminated and the exact nature of the contaminant remain unknown. It is important to determine how the adulteration happened so that industry and government can take more effective proactive measures to reduce the risk of such adulteration in the future.”

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here